Stay updated with breaking news from Nasdaq Bcda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioCardia, Inc. (NASDAQ:BCDA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 13,000 shares, a decrease of 29.3% from the April 30th total of 18,400 shares. Currently, 0.1% of the shares of the company are sold short. […]
BioCardia, Inc. (NASDAQ:BCDA – Get Rating) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totalling 27,400 shares, a drop of 26.9% from the March 15th total of 37,500 shares. Based on an average daily trading volume, of 26,600 shares, the days-to-cover ratio is […]
BioCardia (NASDAQ:BCDA – Get Rating)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 363.92% from the company’s current price. HC Wainwright also issued […]
SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...
Wall Street analysts predict that BioCardia, Inc. (NASDAQ:BCDA – Get Rating) will report $190,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for BioCardia’s earnings, with estimates ranging from $130,000.00 to $250,000.00. BioCardia reported sales of $70,000.00 during the same quarter last year, which indicates a positive year-over-year growth […]